JP2021530507A - 神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法 - Google Patents

神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法 Download PDF

Info

Publication number
JP2021530507A
JP2021530507A JP2021501277A JP2021501277A JP2021530507A JP 2021530507 A JP2021530507 A JP 2021530507A JP 2021501277 A JP2021501277 A JP 2021501277A JP 2021501277 A JP2021501277 A JP 2021501277A JP 2021530507 A JP2021530507 A JP 2021530507A
Authority
JP
Japan
Prior art keywords
compound
cancer
compound according
linker
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021501277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530507A5 (cg-RX-API-DMAC7.html
Inventor
ビー. カール,スティーブン
マッキー,コンスタンス
Original Assignee
マンザニータ ファーマシューティカルズ,インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マンザニータ ファーマシューティカルズ,インク. filed Critical マンザニータ ファーマシューティカルズ,インク.
Publication of JP2021530507A publication Critical patent/JP2021530507A/ja
Publication of JP2021530507A5 publication Critical patent/JP2021530507A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021501277A 2018-07-18 2019-07-17 神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法 Pending JP2021530507A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862700131P 2018-07-18 2018-07-18
US62/700,131 2018-07-18
PCT/US2019/042253 WO2020018700A1 (en) 2018-07-18 2019-07-17 Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof

Publications (2)

Publication Number Publication Date
JP2021530507A true JP2021530507A (ja) 2021-11-11
JP2021530507A5 JP2021530507A5 (cg-RX-API-DMAC7.html) 2022-07-25

Family

ID=69165153

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021501277A Pending JP2021530507A (ja) 2018-07-18 2019-07-17 神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法

Country Status (6)

Country Link
US (1) US11897928B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823674A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021530507A (cg-RX-API-DMAC7.html)
CA (1) CA3105879A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021000644A (cg-RX-API-DMAC7.html)
WO (1) WO2020018700A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022082312A1 (en) 2020-10-21 2022-04-28 Provincial Health Services Authority Novel cxcr4-targeting compounds
WO2022115772A1 (en) * 2020-11-30 2022-06-02 Manzanita Pharmaceuticals, Inc. Methods for using neurotrophin receptor binding conjugate compositions in the treatment of a neurological condition
WO2025218761A1 (zh) * 2024-04-17 2025-10-23 晶核生物医药科技(上海)有限公司 环状肽类化合物、其药物组合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532560A (ja) * 1998-12-21 2002-10-02 ザヴォス 治療成分を神経細胞に細胞内送達するための化合物
JP2015501315A (ja) * 2011-11-01 2015-01-15 アステックス セラピューティックス リミテッド 置換ベンジルアミン化合物および医療、特にc型肝炎ウイルス(hcv)感染症の治療におけるその使用
WO2016155670A1 (zh) * 2015-04-01 2016-10-06 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US4469774A (en) 1983-03-28 1984-09-04 E. I. Du Pont De Nemours And Company Positive-working photosensitive benzoin esters
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US5232695A (en) 1987-12-23 1993-08-03 G. D. Searle & Co. Method of ameliorating herpes simplex virus infections using purified nerve growth factor
US5683894A (en) 1988-04-29 1997-11-04 University Of California Recombinant nerve growth factor
US5486599A (en) 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
US5094848A (en) 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
US5229500A (en) 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
EP0505357B1 (en) 1989-12-11 1999-03-10 Immunomedics, Inc. Method for antibody targeting of diagnostic or therapeutic agents
CN1061623A (zh) 1990-06-01 1992-06-03 里珍纳龙药品有限公司 睫状神经营养性因子受体
US5169764A (en) 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
US5948384A (en) 1990-09-14 1999-09-07 Syngenix Limited Particulate agents
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
DE69218403T2 (de) 1991-01-07 1997-06-26 Syngenix Ltd Für endocytose geeignete teilchen
TW197439B (cg-RX-API-DMAC7.html) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
ZA922947B (en) 1991-04-23 1993-01-27 Regeneron Pharma Assay systems for neurotrophin activity
DE69231178T2 (de) 1991-08-30 2000-11-23 Syngenix Ltd., Cambridge Nukleinsäure-amplifikation durch polymerase-reaktion
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
DE69228127T2 (de) 1991-11-15 1999-09-02 The Regents Of The University Of California Therapie des zentralnervensystems mit genetisch modifizierten zellen
WO1993010076A1 (en) 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5470997A (en) 1992-04-06 1995-11-28 Biosite Diagnostics Incorporated Amphetamine derivatives and protein and polypeptide amphetamine derivative conjugates and labels
AU4242993A (en) 1992-05-21 1993-12-13 Penn State Research Foundation, The Cultured (taxus) tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds
GB2267502B (en) 1992-05-28 1997-01-22 Aligena Ag Polymeric reaction products for use in immobilized buffered gels and membranes
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
EP0666756B1 (en) 1992-09-14 1999-11-24 Regeneron Pharmaceuticals, Inc. Method of producing analgesia using neurotrophins
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
US5349056A (en) 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
US6410510B1 (en) 1996-05-13 2002-06-25 Regeneron Pharmaceuticals, Inc. Administration modified ciliary neurotrophic factors
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
IL109280A0 (en) 1993-04-15 1994-07-31 Regeneron Pharma Neurotrophins for treatment of depression
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5502037A (en) 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
WO1995007092A1 (en) 1993-09-10 1995-03-16 The University Of Medicine And Dentistry Of New Jersey Blood-brain barrier transporters of neurological agents
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5882941A (en) 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
DE69511860T2 (de) 1994-05-31 2000-02-10 Allergan, Inc. Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine
US7144983B1 (en) 1997-02-03 2006-12-05 Genentech, Inc. Pantropic neurotrophic factors
US5728803A (en) 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors
US5556837A (en) 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5661035A (en) 1995-06-07 1997-08-26 The Regents Of The University Of California Voltage sensing by fluorescence resonance energy transfer
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
WO1997023608A1 (en) 1995-12-22 1997-07-03 Chiron Corporation Compositions and methods for targeting gene delivery vehicles using covalently bound targeting elements
US5767288A (en) 1996-01-05 1998-06-16 California Institute Of Technology Photolabile linkers and probes
JP2000507210A (ja) 1996-01-16 2000-06-13 パナヨタトス,ニコス 小分子送達のためのタンパク質吸蔵
US6406710B1 (en) 1996-01-16 2002-06-18 Nikos Panayotatos Protein occlusion for delivery of small molecules
US5994317A (en) 1996-04-09 1999-11-30 Vical Incorporated Quaternary cytofectins
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JPH10212241A (ja) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Bdnfを安定に含有する製剤
US6197743B1 (en) 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
WO1998022451A1 (en) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
IL133585A0 (en) 1997-06-20 2001-04-30 Baker Norton Pharma Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
WO1999018113A1 (fr) 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
US6486303B1 (en) 1998-04-14 2002-11-26 University Of Medicine & Dentistry Of New Jersey Method for making hormone heterodimers
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
AU782309B2 (en) 1999-03-08 2005-07-21 Gerhart Graupner Methods and compositions for targeted drug delivery
EP1286700A2 (en) 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
CN103270022B (zh) 2010-08-31 2015-08-19 巴勃罗·比咯斯拉达 神经营养蛋白受体激动剂及其作为药物的应用
WO2016144636A1 (en) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
MX2022004876A (es) 2019-10-23 2022-05-13 Manzanita Pharmaceuticals Inc Composiciones de conjugados que se enlazan a los receptores de neurotrofina, metodos de uso y metodos de elaboracion de los mismos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532560A (ja) * 1998-12-21 2002-10-02 ザヴォス 治療成分を神経細胞に細胞内送達するための化合物
JP2015501315A (ja) * 2011-11-01 2015-01-15 アステックス セラピューティックス リミテッド 置換ベンジルアミン化合物および医療、特にc型肝炎ウイルス(hcv)感染症の治療におけるその使用
WO2016155670A1 (zh) * 2015-04-01 2016-10-06 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACS MEDICAL CHEMISTRY LETTERS, vol. 3, JPN6023022339, 2012, pages 1008 - 1012, ISSN: 0005077274 *
ANNALS OF ONCOLOGY, vol. 28, JPN6023022338, 2017, pages 1457 - 1472, ISSN: 0005254883 *

Also Published As

Publication number Publication date
MX2021000644A (es) 2021-08-19
CA3105879A1 (en) 2020-01-23
EP3823674A4 (en) 2022-12-28
WO2020018700A1 (en) 2020-01-23
US20210147499A1 (en) 2021-05-20
US11897928B2 (en) 2024-02-13
EP3823674A1 (en) 2021-05-26

Similar Documents

Publication Publication Date Title
RU2769700C2 (ru) Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo
JP2023539715A (ja) 抗体-薬物コンジュゲートとatm阻害剤との組合わせ
US11359008B2 (en) Compositions and methods for treating HIF-1a over-expressing cancers
CN115806547A (zh) 选择的用于brd9的靶向降解的化合物
EP2359829A1 (en) Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
JP2023502929A (ja) Her2陽性乳がんを抗her2抗体-薬物コンジュゲートと併用してツカチニブで治療する方法
JP2020183445A (ja) 医薬組成物
US20170035836A1 (en) Compositions and methods for treating cancers associated with etbr activation
US20260053799A1 (en) Compounds for treating cancer
US20220324986A1 (en) Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
US12077604B2 (en) Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
US11897928B2 (en) Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
US20230226040A1 (en) Combination therapy comprising an fgfr inhibitor and a kras inhibitor
AU2010236818B2 (en) Combination therapy using an anti-EGFR agent(s) and IGF-1R specific inhibitors
TW202216207A (zh) 抗體-藥物結合物及cdk9抑制劑之組合
JP2024503235A (ja) Cdk2阻害剤の固体形態
CN114302745A (zh) 包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法
CN1342096A (zh) 组胺诱导的协同破坏肿瘤作用
US20200268829A1 (en) Methods and compositions for inhibiting metastases of an endothelin b receptor expressing cancer
KR20080081249A (ko) 17-aag 또는 17-ag, 또는 이 중 어느 하나의 전구약물과 her2 억제제의 조합을 사용하여 유방암을치료하는 방법
JP2021527097A (ja) イブルチニブを含む配合物/組成物
WO2018213770A1 (en) Therapeutic methods
JP2022553269A (ja) ニューロトロフィン受容体結合コンジュゲート組成物、並びにその使用方法及び作製方法
JP6629753B2 (ja) がん治療剤の組合せ
TW202333800A (zh) 抗體-藥物結合物及rasg12c抑制劑之組合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220714

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20220926

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240206